ClinicalTrialsFinder
RecruitingEarly Phase 1NCT05858684

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Sponsor

RenJi Hospital

Enrollment

18 participants

Start Date

May 11, 2023

Study Type

INTERVENTIONAL

Conditions

CAR-T Cell Therapy

Summary

This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GC012F injection for people with car-t cell therapy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGC012F injection

Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.

Locations(1)

Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05858684

Related Trials

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT066432211 location

MB-CART2019.1 in Refractory Multiple Sclerosis

NCT071784311 location

Nutrition OUtReach In Systems of Healthcare

NCT068024064 locations

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

NCT065757121 location

THRIVE-CAR-T Digital App

NCT066652951 location